Genmab A/S (NASDAQ:GMAB) Sets New 12-Month Low – Time to Sell?

Genmab A/S (NASDAQ:GMAB) shares hit a new 52-week low during trading on Monday . The company traded as low as $19.00 and last traded at $19.28, with a volume of 162448 shares changing hands. The stock had previously closed at $19.67.

Analyst Ratings Changes

A number of brokerages recently weighed in on GMAB. Redburn Atlantic started coverage on Genmab A/S in a research report on Tuesday, October 8th. They set a “buy” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Price Performance

The firm has a market capitalization of $12.71 billion, a P/E ratio of 18.65, a PEG ratio of 0.55 and a beta of 0.96. The company has a fifty day moving average of $20.99 and a 200 day moving average of $23.61.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03). The firm had revenue of $816.10 million for the quarter, compared to analyst estimates of $838.20 million. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. During the same quarter last year, the company earned $0.47 earnings per share. On average, sell-side analysts forecast that Genmab A/S will post 1.25 EPS for the current year.

Institutional Investors Weigh In On Genmab A/S

Several institutional investors and hedge funds have recently made changes to their positions in the business. Two Sigma Advisers LP increased its stake in Genmab A/S by 84.1% in the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock valued at $14,996,000 after purchasing an additional 280,900 shares in the last quarter. FMR LLC grew its stake in shares of Genmab A/S by 13.5% in the 3rd quarter. FMR LLC now owns 278,194 shares of the company’s stock valued at $6,782,000 after buying an additional 33,076 shares during the period. Oppenheimer Asset Management Inc. increased its position in Genmab A/S by 6.5% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 232,243 shares of the company’s stock valued at $5,662,000 after buying an additional 14,165 shares in the last quarter. Natixis Advisors LLC raised its stake in Genmab A/S by 29.8% during the 3rd quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock worth $5,036,000 after buying an additional 47,437 shares during the period. Finally, ABC Arbitrage SA bought a new position in Genmab A/S in the fourth quarter worth approximately $3,692,000. Institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.